Valuation Bio-Rad Laboratories, Inc.
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
01:30:02 13/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 362.08 USD | +1.64% |
|
+4.09% | +19.50% |
| 07/08 | RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating | MT |
| 05/08 | RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating | MT |
Company Valuation: Bio-Rad Laboratories, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22,439 | 12,460 | 9,399 | 9,182 | 8,212 | 9,554 | - | - |
| Change | - | -44.47% | -24.57% | -2.31% | -10.57% | 16.34% | - | - |
| Enterprise Value (EV) 1 | 22,439 | 11,868 | 8,992 | 8,730 | 7,874 | 8,805 | 8,589 | 8,448 |
| Change | - | -47.11% | -24.24% | -2.91% | -9.8% | 11.82% | -2.46% | -1.65% |
| P/E | 5.38x | - | -14.8x | -5.03x | 10.9x | 43.5x | 42.5x | 42.8x |
| PBR | - | 1.27x | 1.05x | 1.41x | 1.11x | - | - | - |
| PEG | - | - | - | -0x | -0x | -0.6x | 19.67x | -60.7x |
| Capitalization / Revenue | 7.68x | 4.45x | 3.52x | 3.58x | 3.18x | 3.71x | 3.63x | 3.56x |
| EV / Revenue | 7.68x | 4.24x | 3.37x | 3.4x | 3.05x | 3.42x | 3.26x | 3.15x |
| EV / EBITDA | 33.1x | 17.8x | 16.8x | 18.2x | 17.4x | 21.5x | 19.7x | 18.9x |
| EV / EBIT | 39.3x | 22.7x | 23.7x | 26.4x | 25.3x | 30.6x | 27x | 25.7x |
| EV / FCF | 41.9x | 127x | 24x | - | - | 28.7x | 27.2x | 25.5x |
| FCF Yield | 2.39% | 0.79% | 4.17% | - | - | 3.49% | 3.68% | 3.92% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 140.6 | - | -21.82 | -65.36 | 27.85 | 8.33 | 8.51 | 8.45 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,923 | 2,802 | 2,671 | 2,566 | 2,583 | 2,573 | 2,633 | 2,682 |
| EBITDA 1 | 677.5 | 667.9 | 535.9 | 479.5 | 453.2 | 410.3 | 435 | 446.5 |
| EBIT 1 | 571.2 | 524 | 378.9 | 331.3 | 311.6 | 287.5 | 318.4 | 328.8 |
| Net income 1 | 4,246 | -3,628 | -637.3 | -1,844 | 759.9 | 225 | 230 | 228 |
| Net Debt 1 | - | -592.5 | -407.6 | -452.1 | -337.7 | -749 | -965.4 | -1,107 |
| Reference price 2 | 755.57 | 420.49 | 322.89 | 328.51 | 302.99 | 362.08 | 362.08 | 362.08 |
| Nbr of stocks (in thousands) | 29,918 | 29,824 | 29,145 | 27,997 | 26,975 | 26,738 | - | - |
| Announcement Date | 10/02/22 | 16/02/23 | 15/02/24 | 13/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 43.47x | 3.42x | 21.46x | -.--% | 955.44Cr | |
| 31.83x | 4.29x | 16.61x | 2.32% | 19TCr | |
| 20.57x | 3.56x | 12.52x | 3.28% | 12TCr | |
| 17.2x | 0.2x | 12.44x | 0.76% | 6TCr | |
| 31.77x | 7.93x | 20.18x | 1.25% | 5.46TCr | |
| 37.93x | 3.42x | 11.71x | 2.14% | 5TCr | |
| 36.4x | 6.41x | 20.11x | -.--% | 3.43TCr | |
| 46.2x | 1.31x | 12.01x | 0.16% | 3.11TCr | |
| 41.08x | 7.2x | 25.83x | 0.26% | 2.48TCr | |
| 20.67x | 3.12x | 11.69x | 1.41% | 2.41TCr | |
| Average | 32.71x | 4.09x | 16.46x | 1.16% | 5.97TCr | |
| Weighted average by Cap. | 29.80x | 4.02x | 15.53x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIO Stock
- Valuation Bio-Rad Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
